The launch is a step in the company’s “mission to replace bovine with healthier whole-human milk worldwide by 2040," said Shayne Giuliano, co-founder and CEO of 108Labs”
108Labs has announced the discovery of novel secretory antibody biosynthesis in the development of Colostrupedics infant formula, an animal-free infant formula comprising cell-cultured human milk molecules derived from human mammary cell agriculture and formulated with broadly-neutralising human secretory antibodies.
The company’s ‘whole-human’ formula is formulated with patent-pending human cell-cultured ingredients comprising complex sugars, probiotic HMO, bioactive human proteins, and calorically dense human lipids naturally evolved in mothers.
108Labs claims the formula contains a healthier amino acid pattern, fully human protein sequences, and human oligosaccharides missing from bovine formula. The product is aimed to provide balanced nutrition naturally evolved for newborns alongside antimicrobial antibodies naturally evolved against mucosal pathogens.
"After a long journey, it is an exciting day to emerge with such an innovative product vision and major scientific milestones behind us. 108Labs has long dreamed of a day when mothers do not have to compromise on nutritional or antimicrobial benefits when deciding how to feed their newborns. Launching Colostrupedics whole-human infant formula with the world’s first human secretory antibody ingredient is a major step in our mission to replace bovine with healthier whole-human milk worldwide by 2040," said Shayne Giuliano, co-founder and CEO of 108Labs.